SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001651308-24-000043
Filing Date
2024-04-26
Accepted
2024-04-26 07:15:36
Documents
14
Period of Report
2024-04-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20240426.htm   iXBRL 8-K 40056
2 EX-99.1 a8-kx26apr2024xexhibit991.htm EX-99.1 37214
  Complete submission text file 0001651308-24-000043.txt   206208

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20240426.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20240426_lab.xml EX-101.LAB 21545
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20240426_pre.xml EX-101.PRE 12484
17 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20240426_htm.xml XML 2866
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

IRS No.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 24878588
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)